Research Analysts Offer Predictions for TNDM FY2027 Earnings

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) – Leerink Partnrs issued their FY2027 earnings per share estimates for shares of Tandem Diabetes Care in a research note issued to investors on Tuesday, October 15th. Leerink Partnrs analyst M. Kratky expects that the medical device company will earn ($0.01) per share for the year. The consensus estimate for Tandem Diabetes Care’s current full-year earnings is ($1.76) per share. Leerink Partnrs also issued estimates for Tandem Diabetes Care’s FY2028 earnings at $0.27 EPS.

TNDM has been the subject of a number of other research reports. Barclays boosted their target price on shares of Tandem Diabetes Care from $55.00 to $58.00 and gave the stock an “overweight” rating in a research note on Monday, August 5th. The Goldman Sachs Group started coverage on Tandem Diabetes Care in a report on Friday, October 4th. They set a “neutral” rating and a $46.00 target price for the company. Canaccord Genuity Group assumed coverage on Tandem Diabetes Care in a research note on Thursday, August 8th. They issued a “buy” rating and a $57.00 price target on the stock. Canaccord Genuity Group began coverage on Tandem Diabetes Care in a research note on Thursday, August 8th. They issued a “buy” rating and a $57.00 price objective for the company. Finally, UBS Group raised shares of Tandem Diabetes Care to a “hold” rating in a research note on Friday, August 2nd. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $55.13.

Tandem Diabetes Care Stock Performance

NASDAQ:TNDM opened at $35.34 on Thursday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.38 and a current ratio of 3.05. The stock has a market capitalization of $2.31 billion, a PE ratio of -16.91 and a beta of 1.33. Tandem Diabetes Care has a fifty-two week low of $13.82 and a fifty-two week high of $53.69. The company has a fifty day moving average of $41.98 and a two-hundred day moving average of $41.85.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its earnings results on Thursday, August 1st. The medical device company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.07. Tandem Diabetes Care had a negative return on equity of 41.54% and a negative net margin of 17.15%. The business had revenue of $221.90 million during the quarter, compared to the consensus estimate of $205.63 million. During the same period in the prior year, the company posted ($0.30) EPS. The business’s quarterly revenue was up 13.3% on a year-over-year basis.

Institutional Trading of Tandem Diabetes Care

Several institutional investors have recently made changes to their positions in TNDM. Vanguard Group Inc. increased its holdings in Tandem Diabetes Care by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 7,021,906 shares of the medical device company’s stock valued at $207,708,000 after purchasing an additional 18,571 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Tandem Diabetes Care by 79.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 5,788 shares of the medical device company’s stock worth $171,000 after buying an additional 2,562 shares during the period. GAMMA Investing LLC grew its stake in shares of Tandem Diabetes Care by 55.7% in the first quarter. GAMMA Investing LLC now owns 3,845 shares of the medical device company’s stock valued at $136,000 after buying an additional 1,375 shares in the last quarter. Park Avenue Securities LLC raised its holdings in shares of Tandem Diabetes Care by 20.3% in the 1st quarter. Park Avenue Securities LLC now owns 8,650 shares of the medical device company’s stock valued at $306,000 after buying an additional 1,459 shares during the period. Finally, MCF Advisors LLC lifted its stake in Tandem Diabetes Care by 79.3% during the 1st quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock worth $36,000 after acquiring an additional 445 shares in the last quarter.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.